Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 12, pp 4117–4125 | Cite as

Association of Preoperative Hypercoagulability with Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Liver Resection: A Multicenter Study

  • Xiu-Ping Zhang
  • Teng-Fei Zhou
  • Zhi-Heng Wang
  • Fan Zhang
  • Cheng-Qian Zhong
  • Yi-Ren Hu
  • Kang Wang
  • Zong-Tao Chai
  • Zhen-Hua Chen
  • Meng-Chao Wu
  • Wan Yee Lau
  • Shu-Qun ChengEmail author
Hepatobiliary Tumors
  • 177 Downloads

Abstract

Background

Microvascular invasion (MVI) predicts poor prognosis in patients with hepatocellular carcinoma (HCC). HCC patients with hypercoagulability are prone to develop thrombosis; however, the relationship between preoperative coagulability state, as reflected by the international normalized ratio (INR) level, and MVI remains unclear.

Methods

From January 2009 to December 2012, HCC patients who underwent R0 liver resection (LR) from four cancer centers entered into this study. The overall survival (OS) and recurrence-free survival (RFS) rates were compared using the Kaplan–Meier method and Cox regression analysis.

Results

Of the 2509 HCC patients who were included into this study, 1104 were found to have MVI in the resected specimens. These patients were divided into the low (n = 151), normal (n = 796), and high (n = 157) INR subgroups based on the preoperative INR levels. The low INR subgroup had a significantly higher incidence of MVI than the normal or high INR subgroups (61.6% vs. 41.6% vs. 44.6%; p < 0.001). HCC patients with MVI were significantly more likely to have a low preoperative INR level (p < 0.001); the INR level (p < 0.001) was an independent risk factor of OS and RFS. HCC patients with MVI in the low INR subgroup had significantly worse RFS and OS than the normal or high INR subgroups (median RFS 13.5 vs. 20.2 vs. 21.6 months, p < 0.001; median OS 35.5 vs. 59.5 vs. 57.0 months, p < 0.001).

Conclusions

Preoperative hypercoagulability was associated with poor long-term prognosis in HCC patients with MVI after R0 LR.

Notes

Author contributions

S-QC, WYL, X-PZ, M-CW: Conception and design. S-QC: Financial support. FZ, C-QZ, Y-RH, KW, Z-TC, Z-HC: Provision of study materials or patients. X-PZ, Z-HW: Collection and assembly of data. X-PZ, T-FZ: Data analysis and interpretation. X-PZ, WYL: Manuscript writing. All authors: Final approval of manuscript.

Funding

This study was supported by the Key Project of Natural Science Foundation of China (No. 81730097); grants from the Science Fund for Creative Research Groups (No. 81521091); the National Key Basic Research Program ‘973 project’ (No. 2015CB554000); and the National Natural Science Foundation of China (Nos. 81602523, 81702335).

Disclosure

No potential conflict of interest were disclosed.

Supplementary material

10434_2019_7504_MOESM1_ESM.doc (86 kb)
Supplementary material 1 (DOC 86 kb)
10434_2019_7504_MOESM2_ESM.docx (13 kb)
Supplementary material 2 (DOCX 12 kb)
10434_2019_7504_MOESM3_ESM.doc (84 kb)
Supplementary material 3 (DOC 83 kb)
10434_2019_7504_MOESM4_ESM.docx (29 kb)
Supplementary material 4 (DOCX 28 kb)

References

  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.CrossRefGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  3. 3.
    Marrero JA, Kulik LM, Sirlin C, et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.CrossRefGoogle Scholar
  4. 4.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRefGoogle Scholar
  5. 5.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.CrossRefGoogle Scholar
  6. 6.
    Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–93.CrossRefGoogle Scholar
  7. 7.
    Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721.CrossRefGoogle Scholar
  8. 8.
    Wei X, Li N, Li S, et al. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer. 2017;17(1):304.CrossRefGoogle Scholar
  9. 9.
    Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg. 2016;151(4):356–63.CrossRefGoogle Scholar
  10. 10.
    Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327(16):1128–33.CrossRefGoogle Scholar
  11. 11.
    Campello E, Zanetto A, Spiezia L, et al. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res. 2016;143:118–21.CrossRefGoogle Scholar
  12. 12.
    Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014;40(3):277–83.CrossRefGoogle Scholar
  13. 13.
    Ikezoe T. Diagnosis and management of DIC complicated by hematological malignancies. Rinsho Ketsueki. 2016;57(10):2136–44 (in Japanese).PubMedGoogle Scholar
  14. 14.
    Glass JP, Im GY. DIC in decompensated cirrhosis caused by prothrombin complex concentrate and recombinant activated factor VII: a word of caution. Liver Int. 2017;37(9):1412–13.CrossRefGoogle Scholar
  15. 15.
    Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254(1):108–13.CrossRefGoogle Scholar
  16. 16.
    Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–55.CrossRefGoogle Scholar
  17. 17.
    Schlichtemeier SM, Pang TC, Williams NE, et al. A pre-operative clinical model to predict microvascular invasion and long-term outcome after resection of hepatocellular cancer: the Australian experience. Eur J Surg Oncol. 2016;42(10):1576–83.CrossRefGoogle Scholar
  18. 18.
    Du M, Chen L, Zhao J, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14:38.CrossRefGoogle Scholar
  19. 19.
    Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325–39.CrossRefGoogle Scholar
  20. 20.
    Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15(5):1375–82.CrossRefGoogle Scholar
  21. 21.
    Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):1002–09.CrossRefGoogle Scholar
  22. 22.
    Yamashita YI, Imai K, Yusa T, et al. Microvascular invasion of single small hepatocellular carcinoma ≤ 3 cm: Predictors and optimal treatments. Ann Gastroenterol Surg. 2018;2(3):197–203.CrossRefGoogle Scholar
  23. 23.
    You Z, Chen LP, Ye H. Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma. Pak J Med Sci. 2014;30(2):331–34.CrossRefGoogle Scholar
  24. 24.
    Chen ZH, Zhang XP, Wang H, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB (Oxford). 2019.  https://doi.org/10.1016/j.hpb.2019.02.003.CrossRefPubMedGoogle Scholar
  25. 25.
    Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(3):121–27.CrossRefGoogle Scholar
  26. 26.
    Banerjee S, Wang DS, Kim HJ, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology. 2015;62(3):792–800.CrossRefGoogle Scholar
  27. 27.
    Chou CT, Chen RC, Lee CW, Ko CJ, Wu HK, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging. Br J Radiol. 2012;85(1014):778–83.CrossRefGoogle Scholar
  28. 28.
    Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67(3):526–34.CrossRefGoogle Scholar
  29. 29.
    Renzulli M, Brocchi S, Cucchetti A, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 2016;279(2):432–42.CrossRefGoogle Scholar
  30. 30.
    Ruff SM, Weber KT, Khader A, et al. Venous thromboembolism in patients with cancer undergoing surgical exploration. J Thromb Thrombolysis. 2019;47(2):316–23.CrossRefGoogle Scholar
  31. 31.
    Nasser NJ. Edoxaban for cancer-associated venous thromboembolism. N Engl J Med. 2018;379(1):94–95.PubMedGoogle Scholar
  32. 32.
    Intagliata NM, Argo CK, Stine JG, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: proceedings of the 7th international coagulation in liver disease conference. Thromb Haemost. 2018;118(8):1491–06.CrossRefGoogle Scholar
  33. 33.
    Kinoshita A, Onoda H, Imai N, et al. Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma. Oncology. 2013;85(5):269–77.CrossRefGoogle Scholar
  34. 34.
    Zhu WL, Fan BL, Liu DL, Zhu WX. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res. 2009;29(7):2531–34.PubMedGoogle Scholar
  35. 35.
    Thorson CM, Van Haren RM, Ryan ML, et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery. 2014;155(1):134–44.CrossRefGoogle Scholar
  36. 36.
    Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Russo FP. Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma. Cancers (Basel). 2018;10(11):450.CrossRefGoogle Scholar
  37. 37.
    Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–66.CrossRefGoogle Scholar
  38. 38.
    Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018;4(12):1683–90.CrossRefGoogle Scholar
  39. 39.
    Li JH, Wang Y, Xie XY, et al. Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. Am J Cancer Res. 2016;6(9):2109–16.PubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Xiu-Ping Zhang
    • 1
  • Teng-Fei Zhou
    • 2
  • Zhi-Heng Wang
    • 3
  • Fan Zhang
    • 4
  • Cheng-Qian Zhong
    • 5
  • Yi-Ren Hu
    • 6
  • Kang Wang
    • 1
  • Zong-Tao Chai
    • 1
  • Zhen-Hua Chen
    • 1
  • Meng-Chao Wu
    • 1
  • Wan Yee Lau
    • 1
    • 7
  • Shu-Qun Cheng
    • 1
    Email author
  1. 1.Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.The No. 313 Hospital of PLAHuludaoChina
  3. 3.Department of Hepatic Surgery III, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina
  4. 4.Department of Hepatobiliary SurgeryAffiliated Hospital of Binzhou Medical CollegeYantai CityChina
  5. 5.LongYan First HospitalAffiliated to Fujian Medical UniversityFuzhouChina
  6. 6.Department of General SurgeryWenzhou People’s HospitalWenzhouChina
  7. 7.Faculty of MedicineThe Chinese University of Hong KongShatinChina

Personalised recommendations